Ten63 Therapeutics, is a company combining generative AI and physics-based models to develop first- and best-in-class therapeutics, announced the closing of an oversubscribed $15.9 million Series A financing led by new investor Hatteras Venture Partners. Morpheus Ventures, SOSV, Draper Associates, Alexandria Venture Investments, the Sigma Group and other new investors also participated in the round.